Camouflaged WeChat-based Intervention for Abused Women
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorThe University of Hong Kong
About this trial
Intimate partner violence (IPV) is a major public health issue and human rights threat worldwide, especially for Chinese immigrant women victims in Hong Kong. Interventions that address negative physical and emotional outcomes from IPV could therefore play a crucial role in enhancing empowerment, social support, and healthy lifestyle among these women. The overall objective of this pilot mixed methods study is to determine the feasibility and acceptability of a camouflaged WeChat mini-program-based WOMEN Health intervention for women victims of IPV. This study will evaluate the feasibility and acceptability of a camouflaged WeChat mini-program-based WOMEN Health intervention for women victims of IPV.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Chinese-speaking (Mandarin or Cantonese)
women aged 18 to 45 years
originally from mainland China and have moved to Hong Kong for at least one year
screened positive for IPV during heterosexual relationships in the past year
Disqualifiers
unwilling to provide informed consent
severe chronic diseases (e.g., cancer, heart failure, kidney failure, chronic obstructive pulmonary disease, and HIV/AIDS)
currently experience severe IPV (identified using the revised 11-item Danger Assessment)
Trial design
Design model
Parallel
Treatments tested in this trial
WOMEN Health programme
Behavioral(i) Empowerment (IPV information, ie, 30-min one-to-one interview, WeChat mini-program); (ii) Telephone social support (ie, weekly calls); (ⅲ) Healthy lifestyle intervention (ie, healthy lifestyle information and discussion)
Wait-list control group
Behavioral(i) Healthy lifestyle intervention (ie, discussion and weekly calls for body weight)
Treatment groups
86 Participants
are divided into 2 treatment groupsGroup A: WOMEN Health groupExperimental treatment 1 intervention
Group B: Wait-list control groupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Feasibility and acceptability of the WOMEN Health programme
Feasibility and acceptability will be assessed using a 12-item self-developed questionnaire. Items are rated on a 5-point Likert scale (1-5), with higher scores indicating greater acceptability, satisfaction, and usefulness.
Time frame
Week 12Secondary outcomes
1
Changes in depressive symptoms
Depressive symptoms will be assessed using the Chinese version of the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire measuring depressive symptoms experienced over the past two weeks. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms.
Time frame
Baseline and Week 122
Changes in quality of life
Quality of life will be assessed using the Chinese version of the 12-Item Short Form Health Survey, version 2 (SF-12v2), which measures physical and mental health status. Physical Component Summary (PCS) and Mental Component Summary (MCS) scores range from 0 to 100, with higher scores indicating better quality of life.
Time frame
Baseline and Week 123
Changes in intimate partner violence (IPV)
Intimate partner violence will be assessed using the Chinese version of the Revised Conflict Tactics Scales (CTS2), which measures the frequency and severity of psychological aggression, physical assault, sexual coercion, and injury within intimate relationships. Higher scores indicate greater exposure to intimate partner violence.
Time frame
Baseline and Week 124
Changes in Body Mass Index (BMI)
Body weight will be self-measured by participants at home in the morning under fasting conditions, wearing light clothing and without shoes. Height will be measured at baseline using a wall-mounted stadiometer. BMI will be calculated as body weight in kilograms divided by height in meters squared (kg/m²) and categorized according to the World Health Organization (WHO) recommendations for Asian populations.
Time frame
Baseline and up to 12 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: